These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 14679277)
21. Psoriasis options abound. Ongoing research on Enbrel and Raptiva supports their use in psoriasis treatment. Krueger GG Health News; 2004 Jan; 10(1):10-1. PubMed ID: 15002383 [No Abstract] [Full Text] [Related]
22. [Our experience with infliximab in reclacitrant cases of psoriasis]. Pereiro M; González-Vilas D; Sánchez-Aguilar D; Toribio J Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():43-7. PubMed ID: 19080991 [TBL] [Abstract][Full Text] [Related]
26. Clinical experience of secukinumab in the treatment of erythrodermic psoriasis: a case series. Weng HJ; Wang TS; Tsai TF Br J Dermatol; 2018 Jun; 178(6):1439-1440. PubMed ID: 29265175 [No Abstract] [Full Text] [Related]
27. New development in the treatment of psoriasis--infliximab. Pietrzak A; Chodorowska G; Jazienicka I; Junak-Bojarska A; Roliński J Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):322-7. PubMed ID: 15315008 [TBL] [Abstract][Full Text] [Related]
31. Infliximab for the treatment of extensive plaque psoriasis--regulation, cost and reimbursement. Rabinovich M; Fainaru M Isr Med Assoc J; 2003 Nov; 5(11):817-8. PubMed ID: 14650110 [No Abstract] [Full Text] [Related]
32. Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies. Santos-Juanes J; Coto-Segura P; Mas-Vidal A; Galache Osuna C Br J Dermatol; 2010 May; 162(5):1144-6. PubMed ID: 20222926 [No Abstract] [Full Text] [Related]
33. Infliximab (Remicade) for acute, severe pustular and erythrodermic psoriasis. Lisby S; Gniadecki R Acta Derm Venereol; 2004; 84(3):247-8. PubMed ID: 15202853 [No Abstract] [Full Text] [Related]
34. Efficacy of ustekinumab in nail psoriasis and improvement in nail-associated quality of life in a population treated with ustekinumab for cutaneous psoriasis: an open prospective unblinded study. Rigopoulos D; Gregoriou S; Makris M; Ioannides D Dermatology; 2011; 223(4):325-9. PubMed ID: 22134046 [TBL] [Abstract][Full Text] [Related]
35. Infliximab- and methotrexate-resistant rebound of psoriasis after discontinuation of efalizumab (Raptiva). Thielen AM; Barde C; Saurat JH Br J Dermatol; 2006 Oct; 155(4):846-7. PubMed ID: 16965444 [No Abstract] [Full Text] [Related]
36. Persistent expression of CD26/DPPIV after treatment with infliximab in psoriasis despite clinical improvement. van Lingen RG; van Erp PE; Seyger MM; de Jong EM; de Boer-van Huizen RT; Driessen RJ; van de Kerkhof PC Acta Derm Venereol; 2009; 89(5):518-20. PubMed ID: 19734982 [No Abstract] [Full Text] [Related]
37. A scientific debate: key clinical questions in the management of psoriasis. Stingl G J Eur Acad Dermatol Venereol; 2012 Aug; 26 Suppl 5():1. PubMed ID: 22758910 [No Abstract] [Full Text] [Related]
38. Life-threatening pustular and erythrodermic psoriasis responding to infliximab. Lewis TG; Tuchinda C; Lim HW; Wong HK J Drugs Dermatol; 2006 Jun; 5(6):546-8. PubMed ID: 16774108 [TBL] [Abstract][Full Text] [Related]
39. [Infliximab]. Goujon C; Bachelez H Ann Dermatol Venereol; 2011 Dec; 138(12):839-41. PubMed ID: 22137623 [No Abstract] [Full Text] [Related]
40. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Reich K; Nestle FO; Papp K; Ortonne JP; Wu Y; Bala M; Evans R; Guzzo C; Li S; Dooley LT; Griffiths CE Br J Dermatol; 2006 Jun; 154(6):1161-8. PubMed ID: 16704649 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]